Real world, retrospective study of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma patients
Latest Information Update: 06 Jan 2021
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2021 New trial record
- 26 Dec 2020 Results published in the Advances in Therapy